A 34-year-old male with treatment-resistant schizophrenia is admitted to a strictly smoke-… — USMLE Step 3

A 34-year-old male with treatment-resistant schizophrenia is admitted to a strictly smoke-free inpatient psychiatric unit following a severe exacerbation of psychosis at a group home. He was started on clozapine three weeks ago in the outpatient setting, and his dosage was gradually titrated to $400\text{ mg}$ daily. The patient has a history of smoking two packs of cigarettes daily for the past ten years. Upon admission, he is provided with a transdermal nicotine patch to manage withdrawal symptoms.

Vital signs show a blood pressure of $110/70\text{ mm Hg}$ , heart rate of $105/\text{min}$ , respiratory rate of $16/\text{min}$ , and temperature of $37.1^\circ\text{C}$ ( $98.8^\circ\text{F}$ ). Physical examination is unremarkable except for mild resting tachycardia. A complete blood count obtained upon admission shows an absolute neutrophil count (ANC) of $1,600/\mu\text{L}$ .

Which of the following are appropriate next steps in the monitoring and treatment evaluation of this patient? (Select all that apply)

Monitor for central nervous system toxicity and prepare to proactively decrease the antipsychotic dosageAnswer
Assess serum troponin and C-reactive protein levels to screen for medication-induced myocarditisAnswer
C
Maintain the current antipsychotic dosage because transdermal nicotine replacement sustains hepatic enzyme induction
D
Initiate oral bupropion to support smoking cessation and prevent withdrawal-induced agitation
E
Discontinue the antipsychotic immediately because the absolute neutrophil count indicates impending agranulocytosis

Answer

The correct steps are to monitor for central nervous system toxicity while preparing to proactively decrease the antipsychotic dosage, and to assess serum troponin and C-reactive protein levels to screen for myocarditis.

Clozapine metabolism is heavily reliant on the CYP1A2 enzyme, which is strongly induced by polycyclic aromatic hydrocarbons found in tobacco smoke. When a heavy smoker abruptly stops smoking (e.g., upon admission to a smoke-free facility), this hepatic induction is rapidly lost. This leads to a dangerous accumulation of serum clozapine, increasing the risk for dose-dependent adverse effects like severe sedation and seizures. Because the nicotine patch does not induce CYP1A2, the clinician must anticipate toxicity and prepare to proactively decrease the dosage. Furthermore, clozapine carries a black box warning for myocarditis, which has a peak incidence within the first four weeks of treatment. The patient's resting tachycardia at week 3 necessitates immediate baseline and ongoing evaluation with serum troponin and C-reactive protein (CRP) to screen for subclinical cardiotoxicity.

Step-by-Step Solution

Evaluate the pharmacokinetic impact of hospital admission and smoking cessation on clozapine metabolism.

The loss of polycyclic aromatic hydrocarbons (from tobacco smoke) removes CYP1A2 induction, causing serum clozapine levels to rise significantly despite the nicotine patch.

Anticipating this rise is critical to prevent dose-dependent toxicities, such as severe sedation and seizures, requiring a proactive dose reduction.

Assess the clinical significance of the patient's resting tachycardia during the third week of clozapine therapy.

While tachycardia is a common benign side effect, the 3-to-4-week mark is the peak risk period for potentially fatal clozapine-induced myocarditis.

Guidelines mandate screening symptomatic or newly tachycardic patients during this window with serum troponin and C-reactive protein (CRP).

Interpret the admission absolute neutrophil count (ANC) of

1,600/\mu\text{L}

An ANC

\ge 1,500/\mu\text{L}

is within the acceptable normal range for a patient without Benign Ethnic Neutropenia.

Clozapine can safely be continued without interruption, following the standard weekly laboratory monitoring protocol.

Key Concept

Patients on clozapine require vigilant monitoring for dose-dependent toxicity upon abrupt smoking cessation due to the loss of CYP1A2 induction, as well as prompt evaluation for myocarditis (using troponin and CRP) if resting tachycardia develops during the high-risk first four weeks of therapy.

Question

Answer

Step-by-Step Solution

Key Concept

Common Mistakes

Topics

More questions from this topic